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Exon inclusionDuchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) are two of the most common
inherited neuromuscular diseases in humans. Both conditions are fatal and no clinically available treatments
are able to signiﬁcantly alter disease course in either case. However, by manipulation of pre-mRNA splicing
using antisense oligonucleotides, defective transcripts from the DMD gene and from the SMN2 gene in SMA
can be modiﬁed to once again produce protein and restore function. A large number of in vitro and in vivo
studies have validated the applicability of this approach and an increasing number of preliminary clinical
trials have either been completed or are under way. Several different oligonucleotide chemistries can be
used for this purpose and various strategies are being developed to facilitate increased delivery efﬁciency
and prolonged therapeutic effect. As these novel therapeutic compounds start to enter the clinical arena,
attention must also be drawn to the question of how best to facilitate the clinical development of such
personalised genetic therapies and how best to implement their provision.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Introduction
Inherited neurological disorders have long suffered from a relative
paucity of effective treatment options. Whilst our knowledge of
supportive care along with symptomatic and palliative treatments
has improved considerably over recent decades, the same has not
been true of therapies aimed at the molecular defects themselves,
despite many of the responsible genes and pathological mechanisms
being known. This frustrating situation, however, is starting to
change. We now know enough about the molecular pathogenesis of
an increasing number of the monogenic neurological disorders to be
able to design targeted disease-modifying genetic therapies for the
ﬁrst time. One such disease for which the development of targeted
therapy is already far advanced is Duchenne muscular dystrophy
(DMD). Another disease where such treatment is currently under
rapid development is spinal muscular atrophy (SMA). This review
will explain how the manipulation of RNA splicing can be used as
an effective corrective therapy for these two classic genetic condi-
tions. We outline the molecular pathogenesis and splicing biology ofe; 2′MOE-PS, 2′-O-methoxyethyl
cell-penetrating peptide; DMD,
te morpholino; PPMO, peptide-
l muscular atrophy.
ogy, Anatomy and Genetics,
ks Road, Oxford, United King-
A. Wood).
.V. Open access under CC BY license.DMD and SMA, explain the design and use of antisense oligonucleo-
tides in therapeutic exon skipping and exon inclusion respectively,
and discuss the delivery of oligonucleotide drugs to muscle, heart
and the central nervous system. We conclude with some thoughts
on the future of splicing therapies in clinical practice.
Duchenne muscular dystrophy
DMD is a genetic disease of the muscle caused by mutations in the
DMD gene, which lies at chromosomal locus Xp21 (Emery, 2002). The
condition affects around 1 in 3500 live male births and generally
presents in early childhood with proximal muscle weakness. Affected
boys may present with gross motor delay and there can also be a
non-progressive cognitive impairment of variable degree in around
one third of cases. The usual natural history is one of gradually
progressive weakness so that ambulation is lost by the teenage
years. Histologically there is replacement of skeletal muscle tissue
with ﬁbrofatty inﬁltration (Zhou and Lu, 2010). This can result in a
rubbery pseudohypertrophy of the calf muscles, which is a character-
istic feature of the condition. The depleted muscle ﬁbres show
evidence of dystrophy, with repeating cycles of necrosis, regeneration
and ﬁbrosis resulting in unequal ﬁbre size. The dystrophic process
gradually affects the diaphragm and other respiratory muscles,
eventually leading to respiratory failure, and cardiac muscle is also af-
fected, resulting in a dilated cardiomyopathy (Fayssoil et al., 2010).
Cardiorespiratory failure is the primary cause of mortality in such
patients and death typically occurs in early adulthood. Current treat-
ment options are limited, with supportive care and corticosteroid
treatment being the mainstays of conventional therapy (Bushby et
al., 2010a, 2010b; Moxley et al., 2010). Although advances in such
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over recent decades, there remains a pressing need for disease-
modifying therapy (Eagle et al., 2002).
Molecular pathogenesis of dystrophinopathies
The DMD gene encodes the protein dystrophin (Hoffman et al.,
1987). At least seven major isoforms of differing lengths are encoded
by this gene, each using an alternative intragenic promoter (Muntoni
et al., 2003). The true number of isoforms is likely to be considerably
higher, owing to the presence of multiple alternative splicing events.
However, the full-length skeletal muscle isoform is a 427 kDa protein
3685 amino acids in length that localises to the sarcolemma
(Zubrzycka-Gaarn et al., 1988). Here it plays a structural role, linking
the cytoskeleton to the cell membrane and, via the dystrophin-
associated glycoprotein complex (DAGC), beyond to the extracellular
matrix. This connective function allows for the transmission of force
from the contractile cytoskeletal elements of skeletal myoﬁbres to ex-
tracellular structures. It is also important for maintaining the integrityFig. 1. Dystrophin and the dystrophin-associated glycoprotein complex (DAGC). Top: featur
tant binding sites whilst the rod domain acts as a linker. The central rod domain comprises 2
molecular ﬂexibility. In addition, the rod domain contains further binding sites for actin an
nents of the DAGC, a large multiprotein complex which includes laminin, sarcoglycans, α- a
sociated proteins such as NOS. The N-terminus binds to F-actin, whilst at the other end the c
dystrobrevin. The DAGC protein complex straddles the sarcolemma and binds via laminin tof the muscle cell membrane (Davies and Nowak, 2006). The struc-
ture of full-length dystrophin allows it to carry out this role (see
Fig. 1). On a simplistic level, the protein can be thought of as some-
thing akin to a bungee rope in that its central portion consists of a
long, repetitive “rope-like” region (called the rod domain), whilst at
either end there are molecular “hooks” to allow binding to cytoskele-
tal F-actin at one end (the N-terminus) and to the sarcolemmal DAGC
at the other (the C-terminus). The rod domain is a coiled-coil region
made of 24 spectrin-like repeats interspersed by 4 hinge regions
(Ervasti, 2007). Although the rod domain is generally believed to
have a large degree of functional redundancy in terms of dystrophin’s
mechanical role, it does contain a further actin-binding domain and is
also thought to interact with membrane phospholipids, nNOS and
other cytoskeletal elements such as plectin, intermediate ﬁlaments
and microtubules (Le Rumeur et al., 2010). The major actin-binding
interaction at the N-terminus is mediated by two calponin homology
domains. At the other end of the protein, just proximal to the
C-terminus, a strong interaction takes place with the β-dystroglycan
component of the DAGC via a cysteine-rich domain. The C-terminuses of the dystrophin protein. The N- and C-terminal regions contain functionally impor-
4 spectrin-like repeats interspersed by 4 hinge regions that are thought to help provide
d nNOS. Bottom: dystrophin connects the cytoskeleton to the sarcolemma via compo-
nd β-dystroglycan, sarcospan, dystrobrevin and α1- and β1-syntrophin, as well as as-
ysteine-rich region binds β-dystroglycan and the C-terminus binds to syntrophins and
o the basal lamina of the extracellular matrix.
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With this model in mind, it can easily be appreciated that a mutat-
ed dystrophin protein lacking either of its terminal ends would be
functionally incapable. Indeed DMD patients usually have mutations
that cause loss of the C-terminal domain, resulting in non-functional
dystrophin. However, if a mutation were to lack only part of the
central rod domain, the resulting protein could potentially still func-
tion tolerably well. This is borne out by the existence of the much
milder condition Becker muscular dystrophy (BMD), which is allelic
to DMD (Kingston et al., 1983). In BMD, patients typically express a
truncated dystrophin protein that lacks a portion of the rod domain.
Symptoms usually do not occur until late childhood, adolescence or
adulthood and are generally a lot milder than DMD, with patients
often maintaining ambulation well into middle and older age
(Bushby and Garner-Medwin, 1993). As will be explained later, the
presence of this milder phenotypic form of the disease provides the
basis for how DMD can be treated by splice modulation.
The 2.4 Mb longDMD gene, located at cytogenetic locusXp21.2–p21.1,
has the distinction of being the longest knowngene in the humangenome
(Boyce et al., 1991; den Dunnen et al., 1989). Seventy-nine exons are
encoded by the full-length transcript (Roberts et al., 1993). However,
despite its expansive genomic length, the fully spliced mature mRNA of
full-length dystrophin is only some 14 kb long (Koenig et al., 1987). The
implication of this is that whilst each exon is roughly of the order of
150 bp long (excluding the 2.3 kb ﬁnal exon), they are separated by
much longer introns that on average are about 30 kb long (although
their individual lengths range from 107 bp for intron 14 up to over
319 kb for intron 1 of the brain full-length isoform). This feature of the
DMD locus is likely to partly explain why single or multiple whole exon
deletions are the most commonly found mutations in affected patients.
Since exon–exon junctions do not always fall neatly at the ends of
triplet base codons, deletions of certain exons can cause a shift of theFig. 2. Structure of the DMD gene, including positions of promoters for different isoforms. Th
predominantly expressed in brain (also known as the cortical promoter), skeletal muscle and
and originates from a promoter within intron 29. Dp140 has a promoter in intron 44 and is p
inantly found in Schwann cells. Dp71 is expressed from an intron 62 promoter and is ubiqu
CNS. Also shown are the locations of binding sites for actin, nNOS, dystroglycans and syntr
open reading frame. Each individual exon may coincide with positions 1, 2 or 3 of a codon
the ends of the exons. If the exons ﬁt together, the reading frame is maintained. If an exon (
frame is disrupted and the result is DMD. However, deletion of an exon with ends of the sam
together (the equivalent of BMD). Exons are coloured according to the domain they encode
domain (light green) and C-terminus (red).open reading frame at the site of the new exon–exon junction in the
spliced transcript (see Fig. 2). Such frameshifts invariably lead to the
incorporation of a premature STOP codon in the near downstream
region of the transcript. If such a dystrophin protein were to be made, it
would be nonfunctional and possibly unstable and thus these out-of-
frame mutations cause DMD. In addition, the presence of a premature
termination codon in the middle of a transcript is recognised by the
cell, which activates the nonsense-mediated mRNA decay pathway,
degrading the transcript and curtailing production of aberrant protein
(Buvoli et al., 2007). In contrast to this, if exon deletions occur where
the normal open reading frame is maintained, functional dystrophin is
usually still produced, resulting in the milder BMD phenotype (Monaco
et al., 1988).
Splicing biology of dystrophin
The extreme length of the DMD locus means that the RNA polymer-
ase II enzyme takes around 16 hours to generate a single complete tran-
script (Tennyson et al., 1995). If a cell were to require the
completion of the gene's transcription prior to splicing it, the
whole process would be impossibly unwieldy. By necessity then,
the cell commences pre-mRNA splicing concurrently with tran-
scription. This co-transcriptional property appears to be a com-
mon feature of splicing in general and this impacts upon choice
of available splice sites and on alternative exon selection
(Kornblihtt et al., 2004). One interesting consequence of this
prolonged time period needed for transcription is that rapidly dividing
cells are unable to express dystrophin to any signiﬁcant degree. The aver-
age time between cell divisions for cultured human myoblasts is in fact
also around 16–17 h and so it may be that the paucity of dystrophin ex-
pression in such cells could in part be linked to this transcriptional time
limitation (Blau et al., 1985; Nudel et al., 1988). Indeed, such a large
gene is likely to have highly complex splicing and much remainse full-length dystrophin protein (Dp427) has three separate tissue-speciﬁc promoters,
cerebellar Purkinje cells respectively. The Dp260 isoform is mainly expressed in retina
resent in the CNS and kidney, whilst Dp116 has an intron 55 promoter and is predom-
itously expressed, although it appears to play an especially important role within the
ophins. The diagram also shows how the 79 exons ﬁt together in terms of the normal
in the normal open reading frame. This is represented by three alternative shapes at
or a block of exons) with differently shaped ends is deleted from the gene, the reading
e conﬁguration will not affect the reading frame since the remaining exons will still ﬁt
: N-terminus (blue), rod domain (dark green with hinge regions in grey), cysteine-rich
Fig. 3. Immunohistochemical ﬂuorescent staining of dystrophin in skeletal muscle ﬁbres
(tibialis anterior) in mice. Top: sarcolemmal localisation of dystrophin in a wild-type
(C57 BL/10) mouse. Transverse section of muscle ﬁbres shows generally uniformly
sized angulated fbres with consistent dystrophin staining around the cell membrane Bot-
tom: lack of dystrophin expression in themdxmouse DMD model. The majority of ﬁbres
show no dystrophin expression. However, note the presence of occasional revertant
ﬁbres inmdx leading to small clusters of dystrophin positive ﬁbres, the result of sporadic
naturally occurring exon-skipping events that restore the reading frame.
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ample, that shorter introns are spliced outmore quickly than longer ones.
This would lead to a nonconsecutive exon splicing order, which would
have clear implications for splice-directed therapies (Aartsma-Rus et al.,
2006). Some of the studies into DMD multi-exon splicing (discussed
below) lend support to this hypothesis.
Immunohistochemical staining for dystrophin in the muscle tissue
sections of DMD patients shows an absence of the protein from the
muscle sarcolemmal membrane. However, occasional isolated ﬁbres
can be found that still appear to express correctly localised dystrophin
(see Fig. 3) (Arechavala-Gomeza et al., 2010). These ﬁbres, known as
revertant ﬁbres, are thought to be examples of where, by chance, sec-
ond superadded mutations or intrinsic aberrant splicing events have
led to the missing out or “skipping” of an additional exon or exons in
a way that restores the original correct reading frame, allowing func-
tional protein production (Lu et al., 2000; Klein et al., 1992).Exon skipping in DMD
As can be seen from cases of BMD, loss of a substantial part of the dys-
trophin central rod domain can occur with relatively little impact on pro-
tein function. The idea behind splicing therapy in DMD is therefore to
convert the out-of-frame transcript into an in-frame transcript that
codes for functional protein. This can be achieved by the technique of in-
ducing exon skipping in the mutant transcript, so as to bring it back into
the original reading frame (Aartsma-Rus and van Ommen, 2007). Such
exon skipping can be induced using antisense oligonucleotides (AONs).
These compounds are single-stranded, short lengths of nucleotides(generally not longer than 25 nt) and their sequences are designed so
that they are complementary to a speciﬁc region on a pre-mRNA tran-
script of interest. The sequences usually target either a speciﬁc 5′ or 3′
splice site or else bind to a splicing regulatory element such as an intronic
or exonic splicing enhancer (ISE or ESE) or intronic/exonic splicing si-
lencer (ISS or ESS). Binding of an AON to the target sequence makes it
unavailable to the spliceosome, interfering with the normal splicing
mechanism. In this way it is possible to enhance either the inclusion or
exclusion of a chosen exon from the mature mRNA (see Fig. 4). Some
70% of DMD mutations are intragenic exon deletions and are therefore
potentially amenable to exon-skipping therapy (Aartsma-Rus et al.,
2009a). Mutations are spread across the 79 DMD exons, however there
are speciﬁc ‘hotspot’ regions where deletions are particularly common,
such as between exons 45 and 55 where around 70% of deletions are lo-
cated (Muntoni et al., 2003). AON sequences have in fact been designed
for every internal DMD exon (Wilton et al., 2007). However, so far the
majority of AON development has concentrated on skipping those indi-
vidual exons that will beneﬁt the greatest number of patients. Skipping
exon 51, for example, can potentially be applied to 13% of all DMDmuta-
tions, exon 45 to 8.1% and exon 53 to 7.7% (Aartsma-Rus et al., 2009a).
Exon skipping can also be used to treat nonsense mutations, which com-
prise around 15% of DMD mutations, by skipping the exon that contains
the mutation itself (Spitali et al., 2009; Yokota et al., 2012). Of course, in
such cases the reading framemust still be maintained and so single exon
skipping for these mutations is limited to those exons that are not
frame-shifting. However, this would still apply to around 47% of non-
sense mutation patients.
Double and multi-exon skipping
Targeting single exons to skip can only ever hope to treat selected
groups of DMD patients with amenable exon deletions. The exon
reading frame structure of the gene means that some DMDmutations
(including 47% of small point and frameshift mutations) require at
least 2 exons to be skipped in order to restore or maintain the reading
frame (e.g. an exon 8 deletion requires skipping of exons 6 and 7 and
a point mutation in exon 69 or 70 requires that both these exons be
skipped) (Aartsma-Rus et al., 2009a). Indeed single exon skipping as
a technique can treat at best up to 64% of all DMD patients. However,
if it is possible to skip 2 exons using 2 separate AONs (so-called dou-
ble exon skipping), the proportion of treatable patients increases by
19%, meaning that a total of 83% of all DMD patients can be potentially
treated by single or double exon skipping (Aartsma-Rus et al., 2009a).
If it were possible to effect the simultaneous skipping of more than
2 exons, a greater proportion of patients could potentially be treated
using a repertoire of fewer therapeutic oligonucleotide compounds.
This is because the skipping of a deﬁned set of multiple exons can
potentially correct the reading frame of multiple different exon dele-
tions. At the same time it can also be used to treat point mutations in
any of the skipped exons. For example, although the majority of DMD
deletions occur between exons 45 and 55, it so happens that patients
with speciﬁc deletions of this region in its entirety (exons 45–55
inclusive) are known to have particularly mild BMD phenotypes
(Béroud et al., 2007). This makes it an ideal multi-exon skipping
target. Recently it has been shown that bodywide restoration of
dystrophin expression is in fact possible through multi-exon skipping
of exons 45 to 55 using a cocktail of AONs (Aoki et al., 2012). This
study was done in mdx52 mice that lack Dmd exon 52 and utilised
10 separate AONs intravenously. In another study, double exon skip-
ping of exons 43–44 was shown in cultured patient myotubes using
separate AONs for each exon (Aartsma-Rus et al., 2004). Unexpected-
ly, skipping of the seven consecutive exons 45–51 was also achieved
simply by using two AONs, one for exon 45 and the other for exon
51. The fact that this appears to work suggests that splicing of exons
45–50 may occur prior to exon 44–45 splicing. This is plausible
given that intron 44 is unusually long at 270 kb. A similar explanation
Fig. 4. The principle of antisense-induced exon skipping in DMD. In this example exon 50 of DMD is deleted, causing a frameshift in the resulting spliced mRNA. Addition of an AON
that recognises and hybridises to a regulatory splicing element within the sequence of exon 51, such as an ESE, mediates skipping of this additional exon by the spliceosome. This
corrects the reading frame in the spliced mRNA and restores dystrophin protein production. Although the resulting mRNA lacks an additional portion of the central rod domain, this
has a minimal effect on overall protein function.
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lead to double skipping of exons 8–9 (Aartsma-Rus and van Ommen,
2007). In this case intron 7 is 110 kb whilst intron 8 is only 1.1 kb.
Another use of multi-exon skipping is for the potential treatment of
DMD exon duplications. Duplications, which make up around 5–15% of
mutations (Muntoni et al., 2003), present a challenge to the AON ap-
proach since discriminating the extra copy from the original is general-
ly not feasible and skipping both copies of the exon will often lead to a
frameshift. However, by skipping an additional exon or exons, the
reading frame can again be restored. An exon 44 duplication was ame-
nable to induced exon 43–44 skipping using a combination of AONs in
cultured muscle cells (Aartsma-Rus et al., 2007). However, the effects
of multi-exon skipping on duplications are difﬁcult to predict and de-
pend on which exon is in question. For example, an exon 45 duplica-
tion only required a single AON targeting exon 45. However, a larger
duplication of exons 52–62 proved refractory.
AON chemistry and design
In order to be effective therapeutic agents for the modulation of
splicing, AONs ideally require a number of intrinsic properties. To
start off with, the AON in question should bind in a sequence-
speciﬁc manner to the target RNA transcript; the higher the speciﬁc-
ity, the less the chance of unwanted off-target effects. Secondly, the
AON should be of a chemistry that facilitates cellular uptake and ac-
tivity in the appropriate intracellular compartment. Since splicing
takes place in the nucleus, it is vital to design an AON that localises
to the nucleus once it is taken up. In contrast, an antisense strategy
seeking to utilise the siRNA pathway would best be served by an
AON that remained in the cytoplasm where the processes of RNAi
take place. Thirdly, because of the plethora of nucleases present in
vivo, a well-designed AON should be resistant to nuclease degrada-
tion in order to allow it to reach its desired target intact and to
maximise its potential duration of action once there. In addition to
single-stranded stability, of particular importance for modiﬁed
AONs is their interaction with RNAse H, which degrades RNA bound
in RNA/DNA heteroduplexes. If the desired effect is transcript knock-
down by degradation, the AON should be sensitive to RNAse H when
bound to its target. However, for steric blocking techniques like exon
skipping, the AON/RNA duplex should be resistant and not form a
substrate for this enzyme. Fourthly, as with any drug, the ideal AON
should have favourable pharmacokinetics and pharmacodynamics.
Linked to this is of course the prerequisite that the AON should not
be a toxic compound. Finally, the design of the AON must allow itseffective delivery to the target tissues, whether that be a localised
area such as a speciﬁc organ or brain region or body-wide systemic
delivery such as to the musculature.
An ever-increasing range of different oligonucleotide chemistries
have been developed to try to cope with these desired AON proper-
ties (Deleavey and Damha, 2012; Dias and Stein, 2002; Saleh et al.,
2012). To date, several AON chemistries in particular have been
utilised for splicing manipulation in DMD and SMA: 2′-O-methyl
phosphorothioate (2′OMePS), 2′-O-methoxyethyl phosphorothioate
(2′MOE-PS), phosphorodiamidate morpholino (PMO) and peptide
nucleic acid (PNA) (see Fig. 5). Critically, in all these chemistries
the ability to form Watson–Crick base-pairing with RNA is retained
through the maintenance of the nitrogenous nucleobases in the
correct spatial conformation. The backbone structures of these com-
pounds, however, differ widely.
Phosphorothioates (which include 2′OMePS and 2′MOE-PS) are
more closely related in structure to RNA than PMO or PNA. However,
instead of utilising a phosphodiester link between nucleotides,
the non-bridging oxygen atom of the phosphate group of RNA is
substituted by a sulphur atom. This creates nuclease resistance and
also generates chirality around the phosphorus atom, allowing forma-
tion of stereoisomers. Only the Sp diastereomer is, in fact, nuclease
resistant, whilst the Rp diastereomer remains sensitive (Eckstein,
2002). Importantly, the phosphorothioate backbone modiﬁcation
does not, of itself, confer RNase H resistance. This is believed to be
because the phosphorothioate/RNA heteroduplex adopts a conforma-
tion somewhere between B-form DNA and A-form dsRNA, which is
therefore recognised by RNase H since its conformation approximates
that of an RNA/DNA heteroduplex (Noy et al., 2008). Thus, resistance
to RNase H instead requires 2′-O-modiﬁcations of the ribose residue,
which tend to encourage a more dsRNA-like A-form conformation
when bound in a heteroduplex with RNA (Deleavey and Damha,
2012). By adding a methoxyethyl group instead of a simple methyl
group, 2′MOE-PS further increase nuclease resistance compared to
2′OMePS and also increase target RNA binding afﬁnity, raising their
melting temperature. Phosphorothioates also retain a negative
charge. This greatly aids their solubility and means that they can be
complexed easily together with cationic lipids and proteins. They
also bind to plasma proteins in the circulation, which can signiﬁcantly
increase their half-life (Bennett and Swayze, 2010). However, they
cannot be readily conjugated by covalent means to peptides. The
mechanism by which they bind plasma proteins has yet to be fully
elucidated but may be partly electrostatic or involve the formation
of disulphide bridges with sulphur-containing amino acids.
Fig. 5. Examples of AON chemistries currently in development to treat DMD and SMA. The
structures of RNA and DNA shown for comparison. 2′OMePS are based on RNA but substi-
tute a non-bridging oxygen atom of the phosphate with a sulphur atom, making a
phosphorothioate. Additionally the hydrogen of the 2′ hydroxyl group is substituted for a
methyl group. 2′MOE-PS is essentially the same as 2′OMePS but instead of a methyl
group has a methoxyethyl group. PMO uses a phosphorodiamidate linkage between
morpholine rings instead of the normal ribose phosphate backbone. PNA also utilises an
alternative backbone with peptide linkages between N-(2-aminoethyl) glycine units.
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ribose and the rings are joined together by phosphorodiamidate link-
ages. They are nuclease and RNase H resistant and have no charge on
their backbone at physiological pH. They do not appear to be toxic
and are very stable, the majority of compound being excreted essen-
tially unchanged via the urine (Amantana and Iversen, 2005). Unlikephosphorothioates, they have no net electrical charge and therefore
do not tend to interact with other non-target molecules. Although
this reduces the chance of off-target effects, it also means they cannot
form complexes with delivery vectors via electrostatic interaction.
However, instead of forming non-covalent complexes, it is possible
to covalently conjugate PMOs to various delivery moieties such as
cell penetrating peptides (CPPs). PNAs are another AON chemistry
with neutral charge, giving them similar pharmacokinetic proﬁles to
PMOs (McMahon et al., 2002). The PNA backbone is made of repeat-
ing N-(2-aminoethyl)glycine units with nucleobases attached via
carbonyl linkages. Like PMOs, they are resistant to RNase H and nucle-
ase degradation and have very high target binding afﬁnity. They can
also form triplexes and even have the ability to invade double-
stranded DNA (Nielsen, 2010).
Aside from AON chemistry, a separate issue is that of selecting
which precise sequence to target to induce exon skipping or inclu-
sion. At ﬁrst glance, the most obvious places to target might appear
to be the relevant splice sites themselves along with the intron
branch point. The binding of AONs to these sequences makes them
unavailable to spliceosome components, which must then instead
ﬁnd the next applicable splice site to use. However, by their very
nature, canonical splice sites tend to have conserved consensus
sequences and so targeting these sites has the potential to lead to
widespread non-speciﬁc binding of AONs to other transcripts and
therefore off-target effects on other genes. An alternative option
that has proved effective is to target exonic splicing enhancers
(ESEs). These short sequences, which are less well conserved than
splice sites, bind splicing factors such as SR proteins to promote
usage of a particular splice site. Their intra-exonic location means
they can usually be targeted very speciﬁcally. Once again, the steric
blocking of such a site on a transcript prevents the binding of relevant
protein factors and this is enough to signiﬁcantly alter splice site
usage. For DMD, a large number of AONs targeting ESEs in many
different exons have been designed and tested for exon-skipping
capability in vitro and, in general, those AONs targeting ESEs have
been shown to be more effective than those targeting splice sites
(Aartsma-Rus et al., 2010a). However, choosing the exact sequence
of such AONs is not entirely straightforward. The complexity of the
splicing process and the considerable gaps in our knowledge about
the splicing of complex genes such as DMD mean that the effect on
splicing of a particular AON can only truly be determined
experimentally. Much of AON design for DMD has thus relied on a
semi-empirical approach with progression of experimental data
(Aartsma-Rus et al., 2009b; Popplewell et al., 2009; Wilton et al.,
2007). Deﬁning optimal AON targets for exon 7 inclusion in SMA
(see later) has in large part similarly relied on empirical methods
such as minigene deletion studies of splicing (Singh et al., 2006),
and AON exon walking/tiling (Hua et al., 2007). More recently,
attempts have been made to formalise the process of rational AON
design (Pramono et al., 2012; Aartsma-Rus, 2012). This approach uses
three independent variables: co-transcriptional availability of AON
binding sites within the transcript, presence of ESEs and AON target
length.
Preclinical studies of exon skipping in DMD
An early demonstration of the feasibility of the exon skipping ap-
proach was carried out in myotube cell cultures derived from DMD
patients using 2′OMePS AONs transfected using polyethylenimine
(PEI) to induce skipping of exon 46 (van Deutekom et al., 2001).
Animal models of DMD such as the dystrophic mdx mouse have also
been widely used. This mouse has a naturally occurring mutation in
exon 23 of the Dmd gene that introduces a premature termination
codon (Sicinski et al., 1989). In vitro work on mdx-derived myoblasts
as well as in vivo repeated intramuscular administration demonstrat-
ed that Lipofectin-complexed 2′OMePS could be used to induce exon
175A.G.L. Douglas, M.J.A. Wood / Molecular and Cellular Neuroscience 56 (2013) 169–18523 skipping (Mann et al., 2001, 2002). Further extension of this work
showed that intramuscular injection of 2′OMePS targeting the 3′
splice donor site of exon 23 restored functional levels of dystrophin
in treated muscles (Lu et al., 2003). Intravenous administration of
the same AON compounds resulted in widespread dystrophin
restoration in skeletal muscles but not in heart (Lu et al., 2005).
Subcutaneous administration of 2′OMePS AONs was found to provide
more favourable pharmacokinetics and pharmacodynamics than
intravenous or intraperitoneal routes (Heemskerk et al., 2010).
PMOs have also been used to induce exon skipping in DMD. Intra-
muscular injection of PMO targeting the same 3’ splice donor site in
mdx exon 23 was shown to achieve local exon skipping (Gebski et
al., 2003). PMO has also achieved widespread dystrophin restoration
in mdx muscle following intravenous administration (Alter et al.,
2006; Wu et al., 2010). Repeated long-term intravenous PMO admin-
istration inmdxmice has been shown to signiﬁcantly improve muscle
pathology and locomotor activity (Malerba et al., 2011). Intravenous
PMO has also been tested in the dystrophic dog model, which has a
point mutation at the splice acceptor site of exon 7, leading to exon
exclusion, and which requires skipping of both exons 6 and 8 for
dystrophin restoration. Repeated intravenous administration of a
cocktail of three PMOs (two targeting exon 6 and one targeting
exon 8) over 5 to 22 weeks achieved up to an average of 26% of
normal dystrophin levels (Yokota et al., 2009).
One limitation of using synthetic oligonucleotides is the need for
repeated dosing in order to maintain efﬁcacy over time. One alterna-
tive is to introduce stable DNA copies of the AON sequence into the
desired tissues so that therapeutic antisense sequences can continue
to be expressed indeﬁnitely. The U7 snRNA gene can be modiﬁed in
this way to incorporate an AON sequence targeted to induce exon
skipping in DMD (Goyenvalle et al., 2012). The U7 snRNP is a small ri-
bonucleoprotein involved in histone mRNA processing. The snRNA
component is 62 nucleotides long and undergoes complementary
base pairing with histone pre-mRNA in order to initiate 3′ pre-
mRNA processing. Modifying the central Sm protein binding site of
U7 snRNA functionally inactivates it and by substituting the 5′
anti-histone sequence with an AON sequence, it is possible to induce
exon skipping. When such a construct was administered within an
adeno-associated virus 2 (AAV2) vector tomdxmice by intramuscular
and intra-arterial injection, sustained production of functional dystro-
phin protein was observed (Goyenvalle et al., 2004). Long-termwide-
spread dystrophin restoration was also achieved in mdx mice using
single intravenous injection of a similar AAV1-vectored U1 snRNA
construct targeted to induce skipping of exon 23 (Denti et al.,
2008). However, this same kind of approach has been tested in the
dystrophic dog model and whilst single local administration of
AAV1 U7 snRNAs resulted in correction of dystrophic muscle pheno-
type and improved muscle strength, the number of dystrophin
positive ﬁbres reduced substantially over a 5-year follow-up period,
suggesting that repeated administration may still be required (Vulin
et al., 2012).
Spinal muscular atrophy
As described above, the nature of the dystrophin protein and its
mutated transcripts lends itself ideally to therapeutic correction
through exon skipping. However, whilst this approach works well for
dystrophin, the majority of human proteins are unlikely to be able to
functionally tolerate the signiﬁcant internal deletions of their struc-
tures generated by exon skipping. This means that only a small propor-
tion of genetic diseases are likely to be treatable in this way. However,
the process of exon skipping can be further therapeutically applied to
various other pathological situations: for example to correct the
aberrant usage of cryptic splice sites or, through destructive exon
skipping, to downregulate the expression of a particular gene (see
Aartsma-Rus et al., 2010b; van Roon-Mom and Aartsma-Rus, 2012,for reviews of this topic). Furthermore, exon skipping is not the only
possible outcome of AON usage. By targeting and blocking different
sequence elements such as splicing silencers, it is also possible in
certain cases to use AONs to encourage inclusion of an exon where a
mutation has otherwise caused it to be abnormally skipped. Perhaps
the prime example of this approach can be seen in its application for
the potential treatment of SMA.
SMA is an autosomal recessive neurodegenerative disorder of
motor neurons. It predominantly affects the anterior horn cells
(α-motor neurons) of the spinal cord and affects around 1 in 10,000
live born infants, making it the single most common genetic cause
of infant mortality (Lunn and Wang, 2008; Markowitz et al., 2012;
Pearn, 1978; Prior et al., 2010). The heterozygous carrier rates for mu-
tations are around 1 in 50 inWestern European populations, however
carrier frequencies vary between different ethnic populations
(Sugarman et al., 2012). The clinical picture can be variable and clas-
siﬁcation of SMA is divided into three main types of presentation
depending on age of onset. Classical SMA type I (also known as
Werdnig–Hoffman disease) presents by 6 months of age with gross
motor delay, symmetrical proximal muscle weakness, generalised
hypotonia and other lower motor neuron signs such as fasciculation
(particularly of the tongue) and diminished or absent tendon
reﬂexes. Such patients never achieve the ability to sit unaided and
usually have poor head control. Progression tends to be rapid with in-
creasing weakness affecting both skeletal and bulbar musculature,
leading to swallowing and feeding difﬁculties and an increased risk
of aspiration and respiratory tract infection. Worsening respiratory
failure is the most common cause of mortality and death usually oc-
curs by the age of 2 years. SMA type II typically presents slightly
later, before 18 months of age. These patients can usually sit and
may be able to stand but never achieve independent walking. Scolio-
sis tends to develop with time and respiratory muscle and bulbar
weakness progressively worsens. Death is common in adolescence,
although some patients may survive into their 30s. Type III SMA
(Kugelberg–Welander disease) presents after 2 years with proximal
muscle weakness but is a signiﬁcantly milder condition. All patients
are generally able to walk and few or no respiratory difﬁculties are
encountered. Life expectancy tends to be near normal. Some more
recent classiﬁcations also include type 0 (severe neonatal onset)
and type IV (adult onset) but these are rarer forms.
Molecular pathogenesis of SMA
SMA is caused by homozygous or compound heterozygous muta-
tions in the SMN1 gene which lies at chromosomal locus 5q12.2–
q13.3 (Brzustowicz et al., 1990; Lefebvre et al., 1995). The genomic
organisation of this locus is complex in humans because of the
existence of an inverted duplication of a 500 kb long region of DNA
on the long arm of chromosome 5 (see Fig. 6). This rearrangement is
known to have arisen some 5 million years ago at some point prior
to the divergence of human and chimpanzee evolution (Rochette et
al., 2001). Mice therefore have only a single Smn gene, whilst higher
primates such as chimpanzees generally have multiple copies. Howev-
er, in humans the second copy of SMN has undergone slight mutation,
such that its sequence differs by several nucleotides from the original. 5
single base changes were originally described (Lefebvre et al., 1995),
however subsequent work demonstrated that a number of further
polymorphisms can also be present (Monani et al., 1999). This
human-speciﬁc version is known as SMN2, whilst the original is
SMN1. SMN2 is almost identical to SMN1 and only one of the nucleotide
alterations lies within the coding region (Lefebvre et al., 1995). It
should be noted that the true nature of the SMA locus is likely to be
more complex still, since it is not clear that the inverted repeat conﬁg-
uration always applies and indeed gene conversion events between
SMN1 and SMN2 have been described, indicating substantial variability
in this region (Burghes, 1997; Campbell et al., 1997). Both SMN1 and
Fig. 6. Top: The genomic arrangement of the human SMN1 and SMN2 locus at 5q12.2–q13.3, the result of an inverted duplication event of a 500 kb genomic region encompassing 4
genes: SERF1, SMN1, NAIP and GTF2H2. Note that the complexity of this locus means that this particular conﬁguration may not always apply. Bottom: The normal splicing of SMN1
joins all exons from 1 to 8 together without exclusion. A C > T transition in SMN2 leads to exon 7 exclusion in 90% of transcripts. However, by applying an AON complementary to a
splicing silencer sequence in intron 7 known as ISS-N1, inclusion of exon 7 in the mature mRNA can be restored.
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parts; exons 2a and 2b, and exon 8 is untranslated. Exon 7 is therefore
the ﬁnal coding exon of the gene. The mRNA is some 1.7 kb long and
encodes the survival motor neuron protein, which is 38 kDa in size,
294 amino acids long and is ubiquitously expressed in all tissues.
Splicing biology of SMN1 and SMN2
The coding mutation in SMN2 is a C > T transition at the sixth nu-
cleotide of exon 7 (Monani et al., 1999). This mutation itself is synon-
ymous and so no amino acid change takes place. However, the effect
of this sequence change is to destroy an ESE site, which would usually
bind the splicing factor SF2/ASF, a splice-promoting SR protein
(Cartegni and Krainer, 2002). Simultaneously, the new sequence
acts as a new ESS by promoting binding of the heterogenous ribonu-
cleoprotein hnRNP A1, which negatively regulates splice site usage
(Kashima and Manley, 2003). The relative contributions of these
two opposing mechanisms has been debated, however it has been
suggested that hnRNP A1 may antagonise SF2/ASF binding (Cartegni
et al., 2006; Kashima et al., 2007b). Further studies have in fact iden-
tiﬁed additional intronic sequences in introns 6 and 7 that appear to
bind hnRNP A1/A2 and contribute to exon 7 exclusion in SMN2
(Hua et al., 2008). Of particular importance is the silencing sequence
ISS-N1 in intron 7. This regulatory element was initially identiﬁed by
studying the effects on splicing of small deletions created in an SMN2
minigene (Singh et al., 2006). A combination of mutagenesis analysis
and RNA-afﬁnity chromatography subsequently demonstrated that
ISS-N1 contains two hnRNP A1 binding motifs (Hua et al., 2008).
This inhibitory element is the major target of many AON-based treat-
ment strategies (Hua et al., 2008; Singh et al., 2006). Other splicing
factors such as Htra2β1 and Sam68 have also been implicated in
exon 7 alternative splicing (see Fig. 7) (Hofmann et al., 2000;
Pedrotti et al., 2010). More detailed discussions of SMN splicing regu-
lation can be found in Bebee et al., 2010, and Singh and Singh, 2011.
In any case, this single C > T nucleotide change in SMN2 is enough
to cause skipping of exon 7, leading to the truncated protein variant
SMNΔ7. Exon 7 codes for the C-terminal of the protein, which is im-
portant for protein oligomerisation and stability (Lorson et al.,
1998). This means that SMNΔ7 is rapidly degraded (Lorson andAndrophy, 2000). However, the truncated variant appears to retain
a small amount of residual function and it has been shown that trans-
genic mice expressing SMNΔ7 in the presence of low levels of
full-length SMN have a milder phenotype than those without it (Le
et al., 2005). Whilst the main product of SMN2 is SMNΔ7, a small
proportion (around 10%) of SMN2 transcript still undergoes normal
splicing and so a small amount of normal SMN protein is still
produced (Lefebvre et al., 1995). Since patients with SMA have no
SMN1 but usually have at least one copy of SMN2, enough SMN
protein is present to allow developmental viability. In contrast, mice
(which only have a single Smn gene) suffer embryonic lethality if
Smn is knocked out. SMN2 is therefore partially able to compensate
for loss of SMN1, though only with reduced efﬁcacy. Within most
human populations there are variants of the SMN locus where
secondary duplications have taken place, resulting in two, three,
four or even more copies of SMN2. Each copy of SMN2 is able to con-
tribute cumulatively to the total amount of normal SMN protein pro-
duced and there is a known correlation between levels of functional
SMN protein and disease severity (Lefebvre et al., 1997). This means
that in general, the greater the number of SMN2 copies a patient
has, the milder the clinical phenotype of the disease (McAndrew et
al., 1997). Patients with three or more copies of SMN2 are known to
have mild disease (Mailman et al., 2002). A number of other SMN
isoforms have been described, including variants lacking exon 5
(SMNΔ5), exons 5 and 7 together (SMNΔ5 + 7) and a so-called
axonal-SMN (a-SMN) which retains intron 3 (Gennarelli et al.,
1995; Setola et al., 2007). However, the relevance of these isoforms
to SMA pathogenesis is unclear.
SMN protein
There are multiple functions ascribed to SMN protein, although the
details in many cases remain quite unclear (Eggert et al., 2006). Amongst
its proposed roles, it is needed for small nuclear ribonucleoprotein
(snRNP) assembly, for snRNP recycling in the nucleus and it may also
be involved in the cytoplasmic transport of mRNAs. snRNPs are essential
components of the pre-mRNA splicing apparatus that help mediate the
mechanics of the splicing reaction. They comprise various bound protein
factors, togetherwith short lengths of uridine-rich RNA (snRNAs),which
Fig. 7. Some of the regulatory factors governing exon 7 splicing in SMN1 and SMN2 pre-mRNA. Effective splice inclusion of exon 7 requires the recruitment of U1 snRNP to the 5′
splice site of intron 7 and U2 snRNP to the 3′ splice site of intron 6, along with its auxiliary factor U2AF. In SMN1, recruitment is facilitated by an ESE near the 5′ end of exon 7 that
binds splicing factor SF2/ASF, which may also act in conjunction with hnRNP-Q1 (Chen et al., 2008). An additional ESE in the middle of exon 7 enhances inclusion through recruit-
ment of Htra2β1, which itself binds SRp30c and hnRNP-G (Young et al., 2002; Hofmann and Wirth, 2002). Two further sequence elements in intron 7 enhance exon 7 inclusion: ISE
I7-1 and element 2, which is thought to form a hairpin loop (Gladman and Chandler, 2009; Miyajima et al., 2002; Miyaso et al., 2003). In SMN2, the C > T transition (C > U in RNA)
at the sixth nucleotide of exon 7 effectively converts the ESE into and ESS, which binds inhibitory splicing factors such as hnRNP-A1 and Sam68. An upstream sequence in intron 6
known as element 1 also inhibits exon 7 inclusion, as does the ISS-N1 sequence in intron 7, which binds hnRNP-A1. The 3′ end of exon 7 harbours two inhibitory elements: the 3′
cluster and terminal stem-loop 2 (TSL2), which overlaps the 5′ splice site of exon 7 (Singh et al., 2004, 2007). Another inhibitory element is the A > G transition at the hundredth
nucleotide of intron 7 in SMN2, which leads to hnRNP-A1 binding (Kashima et al., 2007a).
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2011). snRNAs are transcribed by RNA polymerase II and thus acquire a
7-methyl guanosine cap. This acts as a signal to export the snRNAs from
the nucleus to the cytoplasm (except forU6 snRNA,which remains local-
ised to the nucleus). In the cytoplasm, variousmaturation processes take
place. SMN protein, complexed together with proteins called Gemins,
directs the addition of a heteroheptamer ring of seven different Sm pro-
teins to each snRNA (Cauchi, 2010). Sm proteins (also known as
Smith-class antigens) act as a scaffold to ensure that the snRNA takes
on and maintains the correct folded structure (Khusial, 2005;
Tan and Kunkel, 1966). Further processing involves trimming of
the 3′ end of the snRNA and hypermethylation of the 7-methyl
guanosine cap to 2,2,7-trimethyl guanosine. The snRNPs are then
reimported to the nucleus where they are trafﬁcked to Cajal
bodies to undergo ﬁnal maturation processing.
The SMN protein complex is in fact also found colocalised with
Cajal bodies themselves in structures called gems (gemini of coiled
bodies), where it may play a role in snRNP recycling (Liu and
Dreyfuss, 1996). Thus, SMN is vital to the cellular turnover of snRNPs
and without it splicing is likely to be impaired. However, the patho-
genesis of SMA does not appear to be simply down to a global
dysregulation of splicing. An exon-array study of alternative splicing
in the spinal cord of SMNΔ7 mice, which are null for Smn but express
human SMN2 and SMNΔ7 and live for up to 14 days, showed that the
majority of splicing changes only occurred late in the disease process
(Bäumer et al., 2009). Thus, the precise pathogenic mechanism of
SMA remains somewhat unclear. In particular, the reason why there
should be a predilection of the disease for a speciﬁc subset of motor
neurons, with relative sparing of other tissues, remains to be under-
stood. Studies in mouse models of SMA have shown there are cell-
and tissue-speciﬁc perturbations in snRNP repertoire and it may be
that the pattern of speciﬁc splicing abnormalities in motor neurons
is sufﬁcient to cause cell death (Zhang et al., 2008; Gabanella et al.,2007). Interestingly, it has recently been reported that motor neurons
express signiﬁcantly lower levels of functional SMN protein from
SMN2 compared to other spinal cord cells (Ruggiu et al., 2012). This
appears to be due to some kind of intrinsic inefﬁciency of motor neu-
rons to splice exon 7, which leads to a negative feedback mechanism
that affects SMN2 splicing itself. This may help explain motor
neurons' selective vulnerability in SMA.
It has also been suggested that the pool of snRNPs involved in the
minor spliceosome (a complex which facilitates the splicing of rare
introns that often have the sequences AT/AC at their splice sites rath-
er than the usual GT/AG) is more signiﬁcantly affected by low SMN
levels owing to the a priori lower expression levels of its constituent
snRNAs and proteins (Coady and Lorson, 2011). Studies of SMA
patient-derived lymphoblasts have indeed demonstrated low levels
of minor spliceosome snRNPs and altered splicing of minor introns
(Boulisfane et al., 2011). Although such AT/AC introns (also known
as U12-dependent introns) are estimated to account for only around
0.34% of all vertebrate introns, they are found in higher densities in
genes coding for voltage-gated ion channels, many of which are
expressed in neuronal and muscular tissues (Levine and Durbin,
2001; Wu and Krainer, 1999). In this way, impaired function of the
minor splicing pathway could conceivably account for the selective
neuromuscular dysfunction in SMA. However, this hypothesis
remains uncertain. Indeed, in a Drosophila model of SMA, no defects
of minor class intron splicing were found, despite decreased levels
of minor class snRNAs. In addition, restoring low levels of SMN
expression rescued larval lethality and locomotion defects without
restoring snRNA levels (Praveen et al., 2012).
Another possible explanation may relate to SMN’s function in the
cytoplasmic transport of mRNAs (Rossoll and Bassell, 2009). Lower
motor neurons are generally extremely long cells and the axons of
those supplying the lower limbs may reach over 1 m in length.
mRNAs are transported from the nucleus along axons towards the
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be achieved in a more responsive and dynamic way following various
stimuli (Lin and Holt, 2008). SMN has been found localised to gran-
ules within primary motor neuron growth cones that contain ribonu-
cleoproteins (Zhang et al., 2006). However, the interpretation of
these ﬁndings remains somewhat uncertain, since only a limited
proportion of endogenous SMN protein was seen to colocalise with
its Gemin binding partners within axons. An interaction between
SMN and hnRNP R and hnRNP Q has been shown (Rossoll et al.,
2002). These interact with β-actin mRNA and it has been demonstrat-
ed that decreased SMN leads to decreased β-actin mRNA and protein
in axonal growth cones (Rossoll et al., 2003).
Exon inclusion in SMA
Notwithstanding the fact that the precise pathogenesis of SMA
remains unclear, a valid treatment strategy for this disease is to
seek to restore the expression of normal SMN protein. The presence
in humans of the SMN2 gene provides a unique opportunity through
which to achieve this. One option is simply to preferentially increase
the expression of SMN2 in order to boost the total amount of tran-
script, about 10% of which will produce functional SMN protein.
Another option is to manipulate SMN2 splicing so as to favour reten-
tion of exon 7. A number of different strategies can be employed to in-
crease exon 7 usage (Bebee et al., 2010). On the one hand, inhibitory
splicing elements such as ISS-N1 can be antagonised, for example by
masking these sequences with an AON (see Fig. 8). Alternatively, pos-
itively acting splicing factors can be recruited, for example through
the use of bifunctional oligonucleotides whose sequence contains an
AON but which also carries a splicing-factor binding site. The avail-
ability of alternative splice sites can be modulated via AON masking,
and even ready-made correctly spliced transcripts can be introduced
through the process of trans-splicing.
Preclinical studies of exon 7 inclusion in SMA
AONs have been used to induce exon 7 inclusion by targeting in-
hibitory cis-acting sequences. This approach was shown to increase
SMN2 exon 7 inclusion in SMA ﬁbroblasts (Hua et al., 2007). 2′Fig. 8. SMN1 pre-mRNA is correctly spliced to generate full-length SMN. However, in
SMN2 skipping of exon 7 occurs in around 90% of transcripts, leading to hypofunctional
SMNΔ7, whilst the other 10% remain correctly spliced. Exon 7 inclusion in SMN2 can be
induced by application of an antisense oligonucleotide (AON) targeting the inhibitory
splicing element ISS-N1.MOE-PS AONs targeting the ISS-N1 sequence in SMN2 intron 7
achieved signiﬁcantly increased levels of full-length SMN2 transcript
in liver and kidney of a humanised SMA mouse model after twice
weekly intravenous injections (Hua et al., 2008). These mice are
hemizygous or wild type for mouse Smn but also have a copy of
human SMN2. Targeting ISS-N1 with AONs has proven a potent meth-
od of promoting exon 7 inclusion; so much so that even a short 8-mer
2′OMePS AON binding to this region was still able to restore exon 7 in
human SMA ﬁbroblasts (Singh et al., 2009). A study of repeated intra-
cerebroventricular (ICV) injection in the SMNΔ7 mouse model
(Smn−/−; SMN2+/+; and SMNΔ7+/+) showed that bilateral ICV injec-
tion of newborn mice with 2′OMePS AON resulted in signiﬁcant in-
creases in SMN protein expression in brain and spinal cord at P12
(Williams et al., 2009). Body weight and motor function were also
partially corrected, however the repeated ICV injection regimen
caused signiﬁcant mortality. Subsequently, another study by Hua et
al., 2010, using ICV infusion of the same 2′OMePS chemistry targeting
the same ISS site failed to show any positive effect on SMN2 exon 7 in-
clusion and also detected a proinﬂammatory effect in brain and spinal
cord. By contrast, the same study demonstrated that ICV infusion of a
2′MOE-PS chemistry led to increased exon 7 inclusion and SMN pro-
tein restoration in the central nervous system (CNS) of SMA type III
mice without any proinﬂammatory effect (Hua et al., 2010). These
mildly affected mouse models have four copies of human SMN2 and
are null for the endogenous mouse gene (Smn−/−) through knockout
replacement of exon 7 with a HRPT cassette (Hsieh-Li et al., 2000). 2′
MOE-PS was delivered to adult mice by micro-osmotic pump over 7
days. When applied to heterozygous (Smn+/−) animals of this same
model type, spinal cord tissue demonstrated around 90% exon 7 in-
clusion even up to 6 months later.
PMO AONs have also been used to encourage exon 7 inclusion in
SMAmouse models (Porensky et al., 2012). In this case, newborn het-
erozygous SMNΔ7 mice received single ICV injections of PMO
targeting ISS-N1, resulting in increased full-length SMN2 transcript,
SMN protein and a prolonged increase in survival from 15 to
>100 days. This study also found that delayed ICV injection at P4
was less effective than injection at P0 and that comparing P0 com-
bined ICV and IV administration, dual P0 and P30 ICV injection and
single P0 ICV injection all resulted in similar efﬁcacies in terms of sur-
vival (Porensky et al., 2012). Intriguingly, a study of early peripheral
2′MOE-PS AON administration (two 50 μg/g subcutaneous injections
between P0 and P3) versus direct CNS administration via ICV injection
(a single 20 μg dose at P1) in a severe SMAmouse model showed that
peripheral systemic AON delivery was strikingly more effective than
ICV injection at extending lifespan (Hua et al., 2011). These results
were in spite of the ﬁnding that CNS levels of restored SMN expres-
sion were not as great after systemic administration as they were
following ICV administration, suggesting an important role for periph-
eral SMN function in the disease process. However, the relatively in-
creased permeability of the blood–brain barrier in neonatal mice is
likely to have allowed passage of AON into brain and spinal cord and
so the precise interpretation of this ﬁnding is tricky, since it is hard to
judge the true dose of peripheral AON reaching the CNS in these
mice and to know how comparable this is to the ICV dose. The CNS
biodistribution of an AON is likely to vary greatly depending on wheth-
er it is delivered systemically or by ICV injection. It may therefore be
that, even though overall SMN levels in CNS were lower in this study,
enough peripherally administered AON reached the correct subset of
neurons to achieve a signiﬁcantly increased phenotypic effect.
A variant on the AON theme has been the development of bifunc-
tional oligonucleotides. These compounds contain an antisense
sequence but also have an additional sequence element such as a bind-
ing site for a splicing factor. 2′OMePS bifunctional oligonucleotides par-
tially complementary to SMN2 exon 7 and with a tail mimicking an ESE
have been used to recruit SF2/ASF, thereby upregulating exon 7 inclu-
sion in SMA patient ﬁbroblasts (Skordis et al., 2003). Furthermore,
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upregulate full-length SMN2 through recruitment of SR proteins for
exon 7 splicing following neonatal ICV injection (Baughan et al.,
2009). More recently, similar constructs of bifunctional 2′-O-methyl
RNAs targeting ISS-N1 and recruiting SF2/ASF and Htra2β1 signiﬁcant-
ly increased CNS SMN protein, bodyweight and survival following
ICV injection in SMNΔ7 mice (Osman et al., 2012). In a similar vein,
Cartegni and Krainer (2003) reported the development of a chimeric
type of compound for SMA treatment by inducing exon-speciﬁc splic-
ing enhancement by small chimeric effectors (ESSENCE). An AON
(PNA) is linked to a minimal RS domain targeted to the affected
exon. The RS domain mimics the function of SR proteins to increase
association of the spliceosome with the exon. This appeared to work
in vitro but has not been tested in vivo.
A further extension of the AON-based strategy that parallels
developments in the DMD ﬁeld has been the use of anti-SMN U7
snRNA (Madocsai et al., 2005). By targeting the intron 7/exon 8 junc-
tion, an anti-SMN U7 snRNA was able to increase SMN protein levels
in SMA patient ﬁbroblasts (Madocsai et al., 2005). A similar approach
has been demonstrated using modiﬁed U7 snRNAs complementary to
a number of different target sequences within exon 7 and intron 7
(Marquis et al., 2007). There are a number of advantages to using
snRNA-incorporated AONs. Since snRNPs are expressed in the nucleus
where splicing takes place, expressing such constructs in cells automat-
ically leads to their correct intranuclear localisation. snRNAs are also
constitutively expressed at a high level, endogenously processed by
cells and complexed together with proteins, enhancing their stability
and half-life. A feasible strategy for long-term treatment of SMA
would therefore be to introducemodiﬁed snRNA genes intomotor neu-
rons via a viral vector. Such an approach has been proposed using re-
combinant adeno-associated (rAAV) vectors, which are known to
effectively transduce neurons and myocytes (Baughan et al., 2006).
An alternative type of splicing therapy can be mediated via the
process of trans-splicing, whereby the mutated part of a transcript is re-
placed through splicing between two separate RNA molecules: one the
endogenous pre-mRNA and the other an introduced correctly-spliced
version of the same RNA (Mansﬁeld et al., 2004). Trans-splicing can
occur naturally at very low levels, however the frequency of this can
be greatly increased by using an engineered trans-splicing RNA
(tsRNA). These molecules contain a coding domain, a splicing domain
featuring a 3′ splice site, polypyrimidine tract and branch point, and a
binding domain, which is effectively an extended AON sequence that
hybridises to the native transcript and brings the correct target region
into close proximity to facilitate the trans-splicing event. This technique
has been applied to the correction of SMN2 splicing both in vitro and in
vivo, whereby ICV injection of tsRNA molecules into SMNΔ7 mice
resulted in increased CNS levels of SMN protein (Shababi and Lorson,
2012). An optimal target for the trans-splicing event has been identiﬁed
as intron 3.
AONs are not the only compounds able to modulate splicing. A
number of drugs and other small molecules have been tested for
their ability to increase functional SMN protein production from
SMN2. Valproic acid, commonly used as an anti-epileptic, has been
found to activate the SMN2 promoter (Brichta et al., 2003; Sumner
et al., 2003). This is thought to occur through upregulation of the
SR-like splicing factor Htra2β1 and also via its activity as a histone
deacetylase (HDAC) inhibitor, which promotes an open chromatin
conformation leading increased gene expression. Other HDAC inhibi-
tor compounds such as phenylbutyrate (used to treat urea cycle
defects), trichostatin A (an antifungal), and the anticancer agent
suberoylanilide hydroxamic acid have also been shown to upregulate
SMN2 to some degree (Avila et al., 2007; Brahe et al., 2005; Hahnen et
al., 2006). However, despite initial promise of such compounds along
with others like hydroxyurea, riluzole and gabapentin, further trials
to date have not demonstrated signiﬁcant clinical improvements
(Chen et al., 2010; Russman et al., 2003; Miller et al., 2001).Delivery of therapeutic AONs
One of the most signiﬁcant and ever-present challenges facing de-
velopment of any new therapeutic agent is that of drug delivery. This
holds just as true for oligonucleotide-based therapies and indeed
even the most efﬁcient AON in vitro can only ever be as good as its
in vivo delivery system. In DMD, the primary therapeutic target is
skeletal muscle. This itself is no small task, since skeletal muscle typ-
ically makes up between 30 and 40% of total body mass (Janssen et al.,
2000). Added to this, BMD patients with in-frame deletions compara-
ble to those that would result from exon skipping treatments current-
ly in development (e.g. exons 51, 53 and 45–55) have been found to
express at least 40% of the dystrophin protein levels expressed by
controls and so AON delivery must hope to aim for similar levels of
restoration (Anthony et al., 2011). Studies using naked AONs in high
enough doses have been shown to achieve effective delivery to
dystrophic skeletal muscle (Wu et al., 2010). The mechanism by
which muscle uptake is achieved is thought to depend on increased
sarcolemmal permeability. However, the origins of this permeability
are debated. One hypothesis is that since dystrophic muscle lacks
dystrophin, the sarcolemmal membrane is more prone to disruption
through mechanical stress and is in effect ‘leaky’ (Davies and Nowak,
2006). An alternative hypothesis invokes phospholipase A2-induced
membrane permeabilisation following altered calcium channel activa-
tion (Allen and Whitehead, 2010). Either way, increased membrane
permeability is thought to facilitate the passage of AONs into muscle
ﬁbres from the circulation.
In general, the polarity of charged oligonucleotides such as 2′
OMePS is believed to prevent them from directly permeating cell
membranes. However, more recently it has been demonstrated that
such charged oligonucleotides can be directly taken up by cells in cul-
ture via a process called gymnosis (Stein et al., 2010). This original
study utilised locked nucleic acid (LNA) phosphorothioate gapmers
to achieve RNase H-mediated gene silencing in a variety of cell lines
and also in mice following intravenous injection. Subsequently it
has also been reported that 2′OMe phosphodiester, 2′OMePS oligonu-
cleotides, whether ﬂanked by LNA sequences or not, and PNAs can
also be taken up by gymnosis (Torres et al., 2011). The mechanism
by which gymnosis occurs is currently under investigation. However,
nucleic acids are known to be internalised via surface glycoproteins
known as scavenger receptors (Pearson et al., 1993; Saleh et al.,
2006). Such receptors have a broad range of ligands including LDL,
phospholipids and bacterial lipopolysaccharide. A common feature
of scavenger receptor ligands is their polyanionic nature, a property
shared by nucleic acids. Gymnotic uptake of negatively charged
AONs may therefore also occur via this route. However, the extent
to which gymnosis is active in the uptake of AONs in vivo remains
to be established.
Importantly, effective AON delivery in DMD patients must by ne-
cessity also include cardiac muscle. Restoration of dystrophin in the
heart is essential for successful long-term therapy, as evidenced by
the fact that cardiac failure is the major cause of mortality. Indeed,
restoring dystrophin in skeletal muscles alone appears to lead to in-
creased demands on cardiac output, potentially worsening overall
cardiac function (Townsend et al., 2009). Trials of naked AONs in an-
imal models have demonstrated a consistent and signiﬁcant differ-
ence in the ability of AONs to penetrate heart compared to skeletal
muscle. The reasons for this lack of heart delivery are unclear and
this perhaps belies the more fundamental gap in our knowledge
regarding AON uptake.
Conjugated AONs
One way of potentially improving uptake of AONs is through
complexing or conjugating them with various additional carrier com-
pounds. Such compounds can take the form of cationic lipid particles,
180 A.G.L. Douglas, M.J.A. Wood / Molecular and Cellular Neuroscience 56 (2013) 169–185cationic polymers, proteins and nanoparticles (Malik and Roy, 2011).
In particular, much work in recent years has focussed on the use of
so-called cell-penetrating peptides (CPPs) (Margus et al., 2012).
These are short cationic or amphipathic peptides capable of entering
cells and delivering various cargoes across the cell membrane. Early
examples of naturally occurring CPPs were the Tat domain of HIV-1
and the penetratin domain of Drosophila antennapedia (Dupont et
al., 2011). CPPs can either be noncovalently complexed to charged
AONs through electrostatic interaction or else covalently conjugated
to uncharged AONs. However, similar to the uptake of naked AONs,
their mechanisms of cellular internalisation are not fully understood.
The endocytotic pathway is generally thought to be the prevailing
route of entry, although some studies have also suggested direct
translocation across the cell membrane (Lundin et al., 2008;
Rydström et al., 2011).
Conjugation of PMO to peptides (PPMO) and other compounds has
received particular attention from the DMD exon skipping ﬁeld. A
dendrimeric octaguanidine PMO conjugate (Vivo-morpholino) has
been tested in mdxmice with repeated biweekly intravenous injection
resulting in expression of around 50% of normal dystrophin levels
in skeletal muscle and 10% in cardiac muscle (Wu et al., 2009).
Arginine-rich peptides have also been shown to signiﬁcantly improve
the cellular uptake and efﬁcacy of PMOs when covalently conjugated
to them (Moulton et al., 2004). One particular PPMO conjugate
named B-PMOwas found to restore up to 30% of dystrophin protein ex-
pression in cardiac muscle after repeated intravenous injection in mdx
mice (Jearawiriyapaisarn et al., 2008). Intravenous B-PMO treatment
was shown to improve mdxmuscle pathology and strength and to pre-
vent stress-induced cardiac failure in mice (Wu et al., 2008). Peritoneal
injection of an arginine-rich PPMO was also found to be effective at
restoring skeletal muscle dystrophin in mdx mice and also in the phe-
notypically more severe double knock-out (dKO) mouse which lacks
both dystrophin and its homologue protein utrophin (Fletcher et al.,
2007; Goyenvalle et al., 2010). Further reﬁnements and modiﬁcations
of the arginine-rich peptide design have led to development of the
Pip (PMO-internalising peptide) series of CPPs. These peptides have
two cationic arginine-rich domains either side of a hydrophobic central
region and have been shown to improve both skeletal muscle and heart
delivery of PMO in mdx mice (Yin et al., 2011). These peptides are
covalently joined to the equivalent of the 5′ end of the PMO via a
thiol-maleimide linker.
The activity of CPPs can be directed towards a particular tissue by
the inclusion of a tissue-speciﬁc peptide sequence within the design.
The addition to B-PMO of a 7 amino acid-long (ASSLNIA) muscle-
speciﬁc peptide (MSP) found by in vivo phage display created the
chimeric compound B-MSP-PMO, which at low doses was shown to
be highly effective over B-PMO at restoring muscle dystrophin in mdx
mice (Yin et al., 2009). Over 12 weeks, biweekly intravenous injection
of B-MSP-PMO at the relatively low dose of 6 mg/kg resulted in around
50% of normal dystrophin protein levels and 100% of analysed muscle
ﬁbres showing dystrophin positivity (Yin et al., 2010).
One potential concern relating to the use of PPMOsmay be toxicity
at higher doses. Above a certain threshold, some arginine-rich PPMOs
have caused toxic effects in animal models, including lethargy and
weight loss in rats and one report of mild renal tubular damage in
monkeys after repeated dosing (Amantana et al., 2007; Moulton and
Moulton, 2010). Whilst the potential for such effects is an important
issue for drug development, a better understanding of the toxicity
mechanisms involved should in time allow appropriate chemical
modiﬁcations to be made that minimise the side effect proﬁle of
these compounds.
Brain delivery
For the treatment of SMA, a particularly signiﬁcant obstacle
presents itself; to cross the blood–brain barrier (BBB). The centralnervous system requires a tightly regulated physiological environ-
ment in order to function correctly. To maintain this, a cellular barrier
separates the tissues of the brain and spinal cord from the constitu-
ents of plasma. The main interface between CNS tissue and plasma
occurs at the neurovascular unit (NVU), which comprises several
components (Mäe et al., 2011). The main physical barrier is formed
from the endothelial cells of brain capillaries. Surrounding this are
regulatory pericytes, which regulate the integrity of the BBB and lie
within the endothelial basement membrane, making contact
with brain endothelial cell in an extensive network (Armulik et al.,
2011). Beyond this lies a surrounding layer of astrocyte endfoot pro-
cesses which envelops the entire vasculature in a layer connected by
adherens junctions.
The most straightforward route for CNS administration is by direct
injection. Many animal studies of AON treatment for SMA have
utilised this route and intrathecal injection has been shown to
achieve a therapeutically suitable CNS distribution of AON in
non-human primates (Passini et al., 2011). However, direct access
to the CNS remains an invasive procedure attended by concomitant
procedural risks to patients. Since the treatment of neuromuscular
disorders with AONs may require life-long repeated dosing, it would
be highly preferable to be able to administer such agents systemically.
The endothelium in the CNS lacks fenestrations and a continuous net-
work of tight junctions prevents paracellular diffusion or transport
from taking place. Any import or export to the brain must therefore
take place transcellularly via one of several pathways. By taking ad-
vantage of these endogenous pathways such as receptor-mediated
transcytosis and adsorptive transcytosis, it is possible for certain
high-molecular weight drug compounds to enter the CNS (Chen and
Liu, 2012). However, it remains to be seen how well AONs can be
adapted for this approach. Complexing or conjugating AONs to
cationic nanoparticles or cell-penetrating peptides may be able to
facilitate such delivery (Hoyer and Neundorf, 2012). It may also be
that extracellular vesicles in the form of exosomes, the focus of
much ongoing research, will prove capable of delivering certain
kinds of AON across the BBB (Lee et al., 2012).
Clinical trials of splicing therapies in DMD and SMA
The success of AONs in animal models has led to a number of clin-
ical trials in DMD patients. 2′OMePS AONs were the ﬁrst compounds
to enter such trials. Intramuscular injection of 0.8mg PRO051 (also
known as GSK2402968) into the tibialis anterior muscle targeting
skipping of exon 51 resulted in 64–97% of dystrophin positive ﬁbres
and 17–35% of normal dystrophin protein levels (van Deutekom et
al., 2007). This led to a systemic trial of the same compound whereby
12 DMD patients were administered subcutaneous PRO051 weekly
over 5 weeks at doses ranging from 0.5 mg/kg up to 6 mg/kg
followed by a 12-week extension study with all patients receiving
6 mg/kg (Goemans et al., 2011). The mean terminal half-life of the
drug was 29 days. Between 60 and 100% of post-treatment muscle
ﬁbres were dystrophin positive in 10 of 12 patients and the best re-
sponse was expression of 15.6% of normal dystrophin protein levels.
No serious drug-related adverse events were found, however mild
proteinuria and increased urinary alpha-1-microglobulin levels were
detected during the extension period. The study also reported an av-
erage increase of 35.2 m in patients' 6-minute walk test following
treatment. Further clinical trials of GSK2402968 (now known
as drisapersen) are being undertaken to compare subcutaneous
3 mg/kg versus 6 mg/kg dosing over 24 weeks (ClinicalTrials.gov
identiﬁer: NCT01462292). A randomised double-blind phase III trial
in 180 patients is also in progress to assess clinical and functional im-
provement after weekly subcutaneous treatment with drisapersen at
6 mg/kg over one year (ClinicalTrials.gov identiﬁer: NCT01254019).
A recent update from Prosensa/GSK on the data from this trial
(presented at the “RNA and Oligonucleotide Therapeutics” meeting
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has reported a signiﬁcant difference in patients' 6-minute walk dis-
tance after 24 weeks of treatment compared to placebo, and that a
clinically meaningful difference is maintained after treatment for
48 weeks. Additional trials in progress include those looking at safety
and tolerability in ambulant patients (ClinicalTrials.gov identiﬁer:
NCT01153932) and further dose-escalation studies randomised and
placebo-controlled in non-ambulant patients up to 12 mg/kg
(ClinicalTrials.gov identiﬁer: NCT01128855).
PMOs have also been trialled in DMD patients. Intramuscular in-
jections of PMO (AVI-4658) successfully induced exon skipping and
dystrophin protein expression after a dose of 0.9 mg of PMO targeting
exon 51 (Kinali et al., 2009). Subsequently an intravenous PMO
dose-escalation study was carried out on 19 DMD patients (Cirak et
al., 2011). This trial showed good tolerance of PMO (AVI-4658) from
0.5 mg/kg up to 20 mg/kg with no drug-related adverse events after
weekly infusions for 12 weeks. Exon 51 skipping was detected at all
doses and restored dystrophin protein was seen from 2 mg/kg
upwards. Degree of response was variable but the best responses
were in two patients, one of whom had 55% dystrophin positive ﬁbres
onmuscle biopsy of biceps brachii post treatment, and another whose
biopsy had up to 18% of normal dystrophin protein levels. The plasma
half-life of the compound was between 1.6 and 3.6 h. Clinical
improvement was not appreciable over this 12-week time period.
However, further clinical trials are currently under way based in
Ohio, USA, to assess longer term clinical outcomes following
24 weeks (ClinicalTrials.gov identiﬁer: NCT01396239) and then
80 weeks (ClinicalTrials.gov identiﬁer: NCT01540409) of treatment
with AVI-4658 (now also known as eteplirsen). Press releases from
Sarepta Therapeutics regarding progress of this trial (also presented
at the 194th European Neuromuscular Centre International Work-
shop, Naarden, The Netherlands, 7th–9th December 2012) have
reported a signiﬁcant treatment beneﬁt in terms of 6-minute walk
test in patients treated with weekly intravenous eteplirsen at 30
and 50 mg/kg compared to a placebo/delayed treatment cohort at
62 weeks and beyond. Whilst these results appear encouraging, it
should be noted that the patient numbers in this trial remain small
and no completely untreated control group is available for compari-
son beyond 24 weeks. Apart from exon 51 skipping, a phase I/IIa
clinical trial targeting exon 53 skipping with PMO is also currently
in development.
Clinical trials for AON therapies in SMA are some way behind
those for DMD. However, the ﬁrst clinical trials of AONs targeting
SMN2 exon 7 splicing have recently begun (ClinicalTrials.gov identiﬁ-
er: NCT01494701). This trial involves the intrathecal administration
of an AON compound named ISIS SMNRx to assess safety, tolerability
and dosing in children affected by SMA. A number of trials have also
taken place to assess the effects of other non-nucleotide based
drugs in SMA. A small open-label clinical trial of valproate in SMA
type III/IV patients reported increase of muscle strength and function
and another study demonstrated increased SMN2 mRNA levels fol-
lowing valproate treatment in SMA patients and carriers, although
the effect was variable (Brichta et al., 2006; Weihl et al., 2006). The
results of a phase II randomised placebo-controlled trial of valproate
in SMA are awaited (ClinicalTrials.gov identiﬁer: NCT00481013).
Conclusions
The widespread application of splice-modulating therapies in clin-
ical practice requires that a number of important issues are
addressed. The ﬁrst is the issue of optimised systemic delivery and
tissue-speciﬁc targeting, which have been discussed above. The ulti-
mate preferred delivery system for AONs would be one that allowed
oral administration. However, the relatively large size of AONs as
compounds makes it problematic to deliver them intact and at high
enough concentrations to be systemically effective through thegastrointestinal tract. At present the major focus of AON development
is concentrating on more direct routes of systemic delivery such as
subcutaneous and intravenous administration. However, it is likely
that in the longer term, once such drugs have become established as
effective therapies, more attention will be turned to the possibility
of oral AONs. A further practical issue relates to the clinical provision
of such therapies within a healthcare system. It is beyond the scope of
this article to discuss the potential health economics of splicing ther-
apies. However, the prospect of delivering novel personalised oligo-
nucleotide compounds on a patient-by-patient basis is likely to be a
highly complex endeavour, requiring input from multiple areas of
expertise.
Once viable treatments such as AON therapies start to enter clini-
cal use, it is likely that the way diseases such as SMA and DMD are
managed will alter considerably. In both cases, early diagnosis and
treatment will be important, since neither approach is designed to
replace lost tissue. In particular, exon inclusion is not a strategy that
can reverse neuronal cell death in SMA. Rather, the aim of such ther-
apy is to prevent further motor neuron degeneration and in so doing
halt the progression of the disease. Thus, it may well be that the most
effective application of exon inclusion therapy for SMA will require
pre-symptomatic preventative deployment. This would be eminently
feasible in families known to be at risk of having a child with SMA.
Such families are usually those in whom an affected child has already
presented and couples in this position often opt for prenatal genetic
diagnosis in subsequent pregnancies. It has also been suggested that
population-wide carrier screening for SMA should be carried out in
order to help inform reproductive choices, however this approach
remains under debate (Muralidharan et al., 2011). Development of
an effective preventative therapy for SMA would, however,
provide a valid and strong argument for newborn genetic screen-
ing for this condition. Such screening could conceivably be added
to the panel of tests already done on newborn blood-spots (Pyatt
and Prior, 2006). Since the majority of SMN1 mutations include
a deletion of exon 7, a high throughput genetic screen for common
mutations would be possible. Alternatively, novel biomarkers may
become available that would allow early diagnosis (Crawford et
al., 2012).
Disordered pre-mRNA splicing has been implicated in an in-
creasingly large number of medical conditions (Douglas and
Wood, 2011). This review has sought to explain how two of the
classic monogenic disorders of neurology can for the ﬁrst time be
treated through the modulation of endogenous splicing. In the
case of DMD, exon skipping for the most common deletions is rap-
idly approaching mainstream clinical application. However, the
pathway for the development of essentially individualised novel
therapeutic compounds for the treatment of the small numbers of
patients with rarer mutations is less clear (Muntoni et al., 2010).
Whilst this is less of an issue for SMA, it is highly relevant to
DMD, where mutations are spread right across the gene. Further-
more, if double or multi-exon skipping is to become a clinical real-
ity, thought needs to be given to how the use of different yet
complementary AON compounds, which individually may not be
of therapeutic beneﬁt unless used in combination, can be developed
and tested in a way that satisﬁes drug regulatory policy. It may be,
for example, that a new type of streamlined clinical trial pathway
is required speciﬁcally for oligonucleotide drug development; one
that is somehow able to take into account both the necessity of ad-
equate patient safety and the pressure of desperate clinical need.
Whatever the solution, it is clear that the current legislative and
regulatory frameworks that govern drug development were not
designed to cope with sequence-speciﬁc oligonucleotide technolo-
gy. If this kind of truly personalised genetic medicine is to become
widely available and applicable to many patients with many differ-
ent types of mutation, signiﬁcant changes will have to be made to
the regulatory process.
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